TD Asset Management’s Abivax ABVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.39M Sell
14,148
-2,800
-17% -$338K ﹤0.01% 1033
2026
Q2
$2.26M Sell
16,948
-48,600
-74% -$5.5M ﹤0.01% 943
2026
Q1
$7.3M Buy
65,548
+1,646
+3% +$195K 0.01% 721
2025
Q4
$8.62M Buy
63,902
+17,416
+37% +$1.9M 0.01% 694
2025
Q3
$3.95M Buy
+46,486
New +$2.85M ﹤0.01% 825

Other funds holding ABVX

TD Asset Management's ABVX Position: Q3 2026 in Review

TD Asset Management reduced its Abivax (ABVX) stake by 17% in Q3 2026, selling an estimated $338K and leaving 14,148 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

TD Asset Management first reported a position in ABVX in Q3 2025 and has held it in 5 quarters since. The position peaked at $8.62M in Q4 2025. 319 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • TD Asset Management held 14,148 shares of Abivax worth $1.39M as of Q3 2026.
  • TD Asset Management sold 2,800 Abivax shares in Q3 2026, an estimated $338K.
  • Abivax made up ﹤0.01% of TD Asset Management's portfolio in Q3 2026, its #1033 holding.
  • TD Asset Management first reported a position in Abivax in Q3 2025 and has held it in 5 quarters since.
  • TD Asset Management's Abivax position peaked at $8.62M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on TD Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.